AstraZeneca Pharma India DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.74×	0.74×	0.74×	0.74×	0.74×
	1.07×	1.08×	0.73×	1.30×	0.90×
	8.7%	10.3%	12.5%	13.1%	14.8%
	1.30×	1.30×	1.32×	1.26×	1.09×
	2.28×	2.28×	1.97×	1.51×	1.67×
	20.7%	24.4%	17.5%	23.8%	18.1%
	22.8%	22.8%	15.6%	24.8%	18.1%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

ASTRAZEN₹6,299.00

AstraZeneca Pharma India Limited

· Pharma & Health

₹ CrorePeersSANOFICONR PGHL SANOFI SENORES INNOVACAP MOREPENLAB IOLCP FDCMcap ₹15,748 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.74	0.74	0.74	0.74	0.74
Interest Burden (Pretax/EBIT) ×	0.90	1.30	0.73	1.08	1.07
EBIT Margin %	14.84	13.08	12.47	10.26	8.74
Asset Turnover ×	1.09	1.26	1.32	1.30	1.30
Financial Leverage (Assets/Equity) ×	1.67	1.51	1.97	2.28	2.28
ROE (5-step product, year-end total equity) %	18.05	23.79	17.54	24.41	20.66
ROE (owners' profit / average owners' equity) %	18.05	24.84	15.62	22.82	22.82

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.